Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Triptorelin for Ovary Protection in Childhood Onset Lupus

Next Previous
Trial Profile

Triptorelin for Ovary Protection in Childhood Onset Lupus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triptorelin (Primary)
  • Indications Ovarian disorders
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
  • 25 Aug 2011 Planned end date changed from 1 Sep 2008 to 1 Sep 2013 as reported by ClinicalTrials.gov.
  • 25 Aug 2011 Planned end date changed from 1 Sep 2008 to 1 Sep 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top